Taste masking liquids

• US 5,616,621 A
• Filed: 01/30/1995
• Issued: 04/01/1997
• Est. Priority Date: 01/30/1995
• Status: Expired due to Term

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: American Home Products Corporation (Pfizer Inc.)
• Inventors: Go, Zenaida O., Popli, Shankar D.
• Primary Examiner(s): Michl, Paul R.
• Assistant Examiner(s): BENSTON JR, WILLIAM E
• Application Number:
  US08/380,540
• Time in Patent Office: 792 Days
• Field of Search: 514/772.4, 424/440, 424/441, 424/451, 424/465
• US Class Current: 514/772.4
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006

Abstract

There is provided a pharmaceutically acceptable taste masking liquid excipient base for administration of relatively large amounts of unpleasant tasting medicines, said excipient base having higher than normal viscosities due to a combination of polyethylene glycol and cellulosic material.

Claims

1. A pharmaceutical composition comprising (i) a liquid excipient base consisting essentially of water and per 100 milliliters of said base about 5 to about 20 grams of a (a) polyethylene glycol having a molecular weight of about 950 to about 2200, and (b) a cellulosic compound selected from the group consisting of methyl cellulose, hydroxyethycellulose, hydroxypropylcellulose, hydroxyethyl methylcellulose, hydroxyproply methylcellulose, carboxymethyl cellulose, mixtures and salts thereof, the weight ratio of said polyethylene glycol to said cellulosic compound being between about 100:

1 and about 20;

1, and the spindle viscosity of the liquid excipient base being between about 150 and about 1000 centipoises at 50 RPM and 150-1200 centipoises at 10 RPM, and (ii) at least one pharmaceutically active compound selected from the group consisting of antihistamines, decongestants, antitussives, expectorants, non-steroidal anti-inflammatory drugs (NSAIDs) and analgesic drugs, said pharmaceutically active compound being dissolved in the liquid excipient base.

2. The composition of claim 1 wherein the pharmaceutically active compound is an antihistamine selected from the group consisting of chlorpheniramine, brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, diphenhydramine, doxylamine, tripelennamine, cyproheptatine, bromodiphenhydramine, phenindamine, pyrilamine and azatadine.

3. The composition of claim 1 wherein the pharmaceutically active compound is a decongestant selected form the group consisting of pseudoephedrine HCl, phenylpropanolamine and phenylephrine.

4. The composition of claim 3 wherein the pharmaceutically active compound is pseudoephedrine HCl in an amount of about 10 to about 60 milligrams per 5 milliliters of the excipient base.

5. The composition of claim 4 wherein the pharmaceutically active compound is pseudoephedrine HCl in an amount of about 15 to about 30 milligrams per 5 milliliters of the excipient base.

6. The composition of claim 1 wherein the pharmaceutically active compound is an expectorant selected from the group consisting of oterpin hydrate, guaifenesin, potassium iodide, potassium citrate and potassium guaicolsulfonate.

7. The composition of claim 6 wherein the expectorant is guaifenesin in an amount up to about 300 milligrams per 5 milliliters of the excipient base.

8. The composition of claim 7 wherein the guaifenesin is present in an amount of about 100 to about 200 milligrams per 5 milliliters of the excipient base.

9. The composition of claim 1 wherein the pharmaceutically active compound is an antitussive selected from the group consisting of caramiphen, dextromethorphan HBr, codeine phosphate and codeine sulfate.

10. The composition of claim 1 wherein the antitussive is dextromethorphan HBr in an amount of between about 5 and about 20 milligrams per 5 milliliters of excipient base.

11. The composition of claim 10 wherein the antitussive is dextromethorphan HBr in an amount of between about 10 and about 15 milligrams per 5 milliliters of excipient base.

12. The composition of claim 1 wherein the NSAID is selected from the group consisting of ibuprofen, ketoprofen and naproxen.

13. The composition of claim 12 wherein ibuprofen is present in in an amount ranging from about 50 to about 150 milligrams per 5 milliliters of excipient base.

14. The composition of claim 13 wherein ibuprofen is present in in an amount ranging from about 100 to about 150 milligrams per 5 milliliters of excipient base.

15. The composition of claim 12 wherein naproxen is present in in an amount ranging from about 50 to about 250 milligrams per 5 milliliters of excipient base.

16. The composition of claim 15 wherein naproxen is present in in an amount ranging from about 100 to about 150 milligrams per 5 milliliters of excipient base.

17. The composition of claim 1 wherein the analgesic is acetominophen.

18. The composition of claim 17 wherein acetominophen is present in an amount up to about 200 milligrams per 5 milliliters of the excipient base.

19. The composition of claim 18 wherein acetominophen is present in an amount of about 150 to about 175 milligrams per 5 milliliters of the excipient base.

20. A method for taste masking at least one unpleasant tasting pharmaceutically active compound comprising dissolving such unpleasant tasting pharmaceutically active compound into a liquid excipient base consisting essentially of water, polyethylene glycol having a molecular weight of about 950 to about 2200, and a cellulosic compound selected from the group consisting of methyl cellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxyethyl methylcellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, mixtures and salts thereof, the spindle viscosity of the liquid excipient base being between about 150 and about 1000 centipoises at 50 RPM and 150-1200 centipoises at 10 RPM.

21. The method of claim 20 wherein wherein the polyethylene glycol has a molecular weight of between 1400 and about 1600.

22. The method of claim 20 wherein the weight ratio of polyethylene glycol and cellulosic compound is between about 100:

1 and about 20;

1.

23. The method of claim 20 wherein the cellulosic compound is sodium carboxymethyl cellulose.

24. The method of claim 23 wherein the weight ratio of polyethylene glycol and sodium carboxymethylcellulose is between about 100:

1 and about 20;

1.

25. The method of claim 20 wherein the excipient base has a pH of between about 2.5 and about 5.

26. The method of claim 20 wherein the pharmaceutically active compound is selected from the group consisting of antihistamines, decongestants, antitussives, expectorants, non-steroidal anti-inflammatory drugs (NSAIDs) and analgesic drugs.

27. The method of claim 20 wherein the pharmaceutically active compound is an antihistamine selected from the group consisting of chlorpheniramine, brompheniramine, dexchlorpheniramine, dexbrompheniramine, triprolidine, diphenhydramine, doxylamine, tripelennamine, cyproheptatine, bromodiphenhydramine, phenindamine, pyrilamine and azatadine.

28. The method of claim 20 wherein the pharmaceutically active compound is a decongestant selected from the group consisting of pseudoephedrine HCl, phenylpropanolamine and phenylephrine.

29. The method of claim 28 wherein the pharmaceutically active compound is pseudoephedrine HCl in an amount of about 10 to about 60 milligrams per 5 milliliters of the excipient base.

30. The method of claim 29 wherein the pharmaceutically active compound is pseudoephedrine HCl in an amount of about 15 to about 30 milligrams per 5 milliliters of the excipient base.

31. The method of claim 20 wherein the pharmaceutically active compound is an expectorant selected from the group consisting of oterpin hydrate, guaifenesin, potassium iodide, potassium citrate and potassium guaicolsulfonate.

32. The method of claim 31 wherein the expectorant is guaifenesin in an amount up to about 300 milligrams per 5 milliliters of the excipient base.

33. The method of claim 32 wherein the guaifenesin is present in an amount of about 100 to about 200 milligrams per 5 milliliters of the excipient base.

34. The method of claim 20 wherein the pharmaceutically active compound is an antitussive selected from the group consisting of caramiphen, dextromethorphan HBr, codeine phosphate and codeine sulfate.

35. The method of claim 34 wherein the antitussive is dextromethorphan HBr in an amount of between about 5 and about 20 milligrams per 5 milliliters of excipient base.

36. The method of claim 34 wherein the antitussive is dextromethorphan HBr in an amount of between about 10 and about 15 milligrams per 5 milliliters of excipient base.

37. The method of claim 20 wherein the NSAID is selected from the group consisting of ketoprofen, ibuprofen and naproxen.

38. The method of claim 37 wherein ibuprofen is present in in an amount ranging from about 50 to about 150 milligrams per 5 milliliters of excipient base.

39. The method of claim 38 wherein ibuprofen is present in in an amount ranging from about 100 to about 150 milligrams per 5 milliliters of excipient base.

40. The method of claim 37 wherein naproxen is present in in an amount ranging from about 50 to about 250 milligrams per 5 milliliters of excipient base.

41. The method of claim 40 wherein naproxen is present in in an amount ranging from about 100 to about 150 milligrams per 5 milliliters of excipient base.

42. The method of claim 20 wherein the analgesic is acetominophen.

43. The method of claim 42 wherein acetominophen is present in an amount up to about 200 milligrams per 5 milliliters of the excipient base.

44. The method of claim 42 wherein acetominophen is present in an amount of about 150 to about 175 milligrams per 5 milliliters of the excipient base.